PCSK9 and familial hyperaldosteronism: In line with this concept, in our study for the first time we observed decrease of CLC in FH patients treated with PCSK9-i treatment indicates that the likely PCSK9-i related arterial wall foam-cell formation reduction could contribute to the proven CV benefit associated with this treatment (Steffens et al., 2020).